Matrix metalloproteinase-9: A magic drug target in neuropsychiatry?
addiction
autism spectrum disorders
bipolar disorder
epilepsy
major depression
schizophrenia
Journal
Journal of neurochemistry
ISSN: 1471-4159
Titre abrégé: J Neurochem
Pays: England
ID NLM: 2985190R
Informations de publication
Date de publication:
04 Oct 2023
04 Oct 2023
Historique:
revised:
12
09
2023
received:
28
06
2023
accepted:
15
09
2023
pubmed:
4
10
2023
medline:
4
10
2023
entrez:
4
10
2023
Statut:
aheadofprint
Résumé
Neuropsychiatric conditions represent a major medical and societal challenge. The etiology of these conditions is very complex and combines genetic and environmental factors. The latter, for example, excessive maternal or early postnatal inflammation, as well as various forms of psychotrauma, often act as triggers leading to mental illness after a prolonged latent period (sometimes years). Matrix metalloproteinase-9 (MMP-9) is an extracellularly and extrasynaptic operating protease that is markedly activated in response to the aforementioned environmental insults. MMP-9 has also been shown to play a pivotal role in the plasticity of excitatory synapses, which, in its aberrant form, has repeatedly been implicated in the etiology of mental illness. In this conceptual review, we evaluate the experimental and clinical evidence supporting the claim that MMP-9 is uniquely positioned to be considered a drug target for ameliorating the adverse effects of environmental insults on the development of a variety of neuropsychiatric conditions, such as schizophrenia, bipolar disorder, major depression, autism spectrum disorders, addiction, and epilepsy. We also identify specific challenges and bottlenecks hampering the translation of knowledge on MMP-9 into new clinical treatments for the conditions above and suggest ways to overcome these barriers.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fundacja na rzecz Nauki Polskiej
ID : MAB/2018/10
Informations de copyright
© 2023 Nencki Institute. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry.
Références
Abdallah, M. W., Pearce, B. D., Larsen, N., Greaves-Lord, K., Nørgaard-Pedersen, B., Hougaard, D. M., Mortensen, E. L., & Grove, J. (2012). Amniotic fluid MMP-9 and neurotrophins in autism spectrum disorders: An exploratory study. Autism Research, 5, 428-433.
Alaiyed, S., Bozzelli, P. L., Caccavano, A., Wu, J. Y., & Conant, K. (2019). Venlafaxine stimulates PNN proteolysis and MMP-9-dependent enhancement of gamma power; relevance to antidepressant efficacy. Journal of Neurochemistry, 148, 810-821.
Alaiyed, S., & Conant, K. (2019). A role for matrix metalloproteases in antidepressant efficacy. Frontiers in Molecular Neuroscience, 12, 117.
Alaiyed, S., McCann, M., Mahajan, G., Rajkowska, G., Stockmeier, C. A., Kellar, K. J., Wu, J. Y., & Conant, K. (2020). Venlafaxine stimulates an MMP-9-dependent increase in excitatory/inhibitory balance in a stress model of depression. The Journal of Neuroscience, 40, 4418-4431.
Arias, D., Saxena, S., & Verguet, S. (2022). Quantifying the global burden of mental disorders and their economic value. EClinicalMedicine, 54, 101675.
Arout, C. A., Waters, A. J., MacLean, R. R., Compton, P., & Sofuoglu, M. (2019). Minocycline does not affect experimental pain or addiction-related outcomes in opioid maintained patients. Psychopharmacology, 236, 2857-2866.
Batool, S., Raza, H., Zaidi, J., Riaz, S., Hasan, S., & Syed, N. I. (2019). Synapse formation: From cellular and molecular mechanisms to neurodevelopmental and neurodegenerative disorders. Journal of Neurophysiology, 121, 1381-1397.
Beroun, A., Mitra, S., Michaluk, P., Pijet, B., Stefaniuk, M., & Kaczmarek, L. (2019). MMPs in learning and memory and neuropsychiatric disorders. Cellular and Molecular Life Sciences, 76, 3207-3228.
Bertran, A., Khomiak, D., Konopka, A., Rejmak, E., Bulska, E., Seco, J., Kaczmarek, L., Tarragó, T., & Prades, R. (2020). Design and synthesis of selective and blood-brain barrier-permeable hydroxamate-based gelatinase inhibitors. Bioorganic Chemistry, 94, 103365.
Bijata, M., Bączyńska, E., Müller, F. E., Bijata, K., Masternak, J., Krzystyniak, A., Szewczyk, B., Siwiec, M., Antoniuk, S., Roszkowska, M., Figiel, I., Magnowska, M., Olszyński, K. H., Wardak, A. D., Hogendorf, A., Ruszczycki, B., Gorinski, N., Labus, J., Stępień, T., … Wlodarczyk, J. (2022). Activation of the 5-HT7 receptor and MMP-9 signaling module in the hippocampal CA1 region is necessary for the development of depressive-like behavior. Cell Reports, 38, 110532.
Bijata, M., Labus, J., Guseva, D., Stawarski, M., Butzlaff, M., Dzwonek, J., Schneeberg, J., Böhm, K., Michaluk, P., Rusakov, D. A., Dityatev, A., Wilczyński, G., Wlodarczyk, J., & Ponimaskin, E. (2017). Synaptic remodeling depends on signaling between serotonin receptors and the extracellular matrix. Cell Reports, 19, 1767-1782.
Bilousova, T. V., Dansie, L., Ngo, M., Aye, J., Charles, J. R., Ethell, D. W., & Ethell, I. M. (2009). Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. Journal of Medical Genetics, 46, 94-102.
Bobadilla, A.-C., Heinsbroek, J. A., Gipson, C. D., Griffin, W. C., Fowler, C. D., Kenny, P. J., & Kalivas, P. W. (2017). Corticostriatal plasticity, neuronal ensembles, and regulation of drug-seeking behavior. Progress in Brain Research, 235, 93-112.
Bobińska, K., Szemraj, J., Gałecki, P., & Talarowska, M. (2016). The role of MMP genes in recurrent depressive disorders and cognitive functions. Acta Neuropsychiatrica, 28, 221-231.
Broekaart, D. W., Bertran, A., Jia, S., Korotkov, A., Senkov, O., Bongaarts, A., Mills, J. D., Anink, J. J., Seco, J., Baayen, J. C., Idema, S., Chabrol, E., Becker, A. J., Wadman, W. J., Tarragó, T., Gorter, J. A., Aronica, E., Prades, R., Dityatev, A., & van Vliet, E. A. (2021). The matrix metalloproteinase inhibitor IPR-179 has antiseizure and antiepileptogenic effects. The Journal of Clinical Investigation, 131, 138332.
Brown, T. E., Forquer, M. R., Cocking, D. L., Jansen, H. T., Harding, J. W., & Sorg, B. A. (2007). Role of matrix metalloproteinases in the acquisition and reconsolidation of cocaine-induced conditioned place preference. Learning & Memory, 14, 214-223.
Cai, D.-B., Zheng, W., Zhang, Q.-E., Ng, C. H., Ungvari, G. S., Huang, X., & Xiang, Y.-T. (2020). Minocycline for depressive symptoms: A meta-analysis of randomized, double-blinded, placebo-controlled trials. The Psychiatric Quarterly, 91, 451-461.
Cheng, M., Liu, Q., Wang, Y., Hao, Y., Jing, P., Jiao, S., Ma, L., Pan, C., & Wu, Y. (2019). MMP-9-BDNF pathway is implicated in cognitive impairment of male individuals with methamphetamine addiction during early withdrawal. Behavioural Brain Research, 366, 29-35.
Dansie, L. E., Phommahaxay, K., Okusanya, A. G., Uwadia, J., Huang, M., Rotschafer, S. E., Razak, K. A., Ethell, D. W., & Ethell, I. M. (2013). Long-lasting effects of minocycline on behavior in young but not adult fragile X mice. Neuroscience, 246, 186-198.
Dehorter, N., & Del Pino, I. (2020). Shifting developmental trajectories during critical periods of brain formation. Frontiers in Cellular Neuroscience, 14, 283.
Dziembowska, M., Milek, J., Janusz, A., Rejmak, E., Romanowska, E., Gorkiewicz, T., Tiron, A., Bramham, C. R., & Kaczmarek, L. (2012). Activity-dependent local translation of matrix metalloproteinase-9. The Journal of Neuroscience, 32, 14538-14547.
Dziembowska, M., Pretto, D. I., Janusz, A., Kaczmarek, L., Leigh, M. J., Gabriel, N., Durbin-Johnson, B., Hagerman, R. J., & Tassone, F. (2013). High MMP-9 activity levels in Fragile X Syndrome are lowered by minocycline. American Journal of Medical Genetics. Part A, 161A, 1897-1903.
Feng, D., Zhou, J., Liu, H., Wu, X., Li, F., Zhao, J., Zhang, Y., Wang, L., Chao, M., Wang, Q., Qin, H., Ge, S., Liu, Q., Zhang, J., & Qu, Y. (2022). Astrocytic NDRG2-PPM1A interaction exacerbates blood-brain barrier disruption after subarachnoid hemorrhage. Science Advances, 8, eabq2423.
Ferensztajn, E., Skibinska, M., Kaczmarek, M., Losy, J., & Rybakowski, J. K. (2015). Neurobiology and temperament in the offspring of excellent lithium responders. The World Journal of Biological Psychiatry, 16, 272-277.
Fields, G. B. (2019). The rebirth of matrix metalloproteinase inhibitors: Moving beyond the dogma. Cell, 8, 984.
Figiel, I., Kruk, P. K., Zaręba-Kozioł, M., Rybak, P., Bijata, M., Wlodarczyk, J., & Dzwonek, J. (2021). MMP-9 signaling pathways that engage rho GTPases in brain plasticity. Cell, 10, 166.
Fitton, R., Sweetman, J., Heseltine-Carp, W., & van der Feltz-Cornelis, C. (2022). Anti-inflammatory medications for the treatment of mental disorders: A scoping review. Brain, Behavior, & Immunity-Health, 26, 100518.
Garcia-Keller, C., Neuhofer, D., Bobadilla, A.-C., Spencer, S., Chioma, V. C., Monforton, C., & Kalivas, P. W. (2019). Extracellular matrix signaling through β3 integrin mediates cocaine cue-induced transient synaptic plasticity and relapse. Biological Psychiatry, 86, 377-387.
Gkogkas, C. G., Khoutorsky, A., Cao, R., Jafarnejad, S. M., Prager-Khoutorsky, M., Giannakas, N., Kaminari, A., Fragkouli, A., Nader, K., Price, T. J., Konicek, B. W., Graff, J. R., Tzinia, A. K., Lacaille, J.-C., & Sonenberg, N. (2014). Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses Fragile X Syndrome-like phenotypes. Cell Reports, 9, 1742-1755.
Go, B. S., Sirohi, S., & Walker, B. M. (2020). The role of matrix metalloproteinase-9 in negative reinforcement learning and plasticity in alcohol dependence. Addiction Biology, 25, e12715.
Gorkiewicz, T., Balcerzyk, M., Kaczmarek, L., & Knapska, E. (2015). Matrix metalloproteinase 9 (MMP-9) is indispensable for long term potentiation in the central and basal but not in the lateral nucleus of the amygdala. Frontiers in Cellular Neuroscience, 9, 73.
Gould, T. D., Picchini, A. M., Einat, H., & Manji, H. K. (2006). Targeting glycogen synthase kinase-3 in the CNS: Implications for the development of new treatments for mood disorders. Current Drug Targets, 7, 1399-1409.
Hannocks, M.-J., Zhang, X., Gerwien, H., Chashchina, A., Burmeister, M., Korpos, E., Song, J., & Sorokin, L. (2019). The gelatinases, MMP-2 and MMP-9, as fine tuners of neuroinflammatory processes. Matrix Biology, 75-76, 102-113.
Hodebourg, R., Kalivas, P. W., & Kruyer, A. (2022). Extrasynaptic therapeutic targets in substance use and stress disorders. Trends in Pharmacological Sciences, 43, 56-68.
Huntley, G. W. (2012). Synaptic circuit remodelling by matrix metalloproteinases in health and disease. Nature Reviews. Neuroscience, 13, 743-757.
Janusz, A., Milek, J., Perycz, M., Pacini, L., Bagni, C., Kaczmarek, L., & Dziembowska, M. (2013). The fragile X mental retardation protein regulates matrix metalloproteinase 9 mRNA at synapses. The Journal of Neuroscience, 33, 18234-18241.
Kaczmarek, L. (2018). From c-Fos to MMP-9: In control of synaptic plasticity to produce healthy and diseased mind, a personal view. Postępy Biochemii, 64, 101-109.
Kennedy-Wood, K., Ng, C. A. S., Alaiyed, S., Foley, P. L., & Conant, K. (2021). Increased MMP-9 levels with strain-dependent stress resilience and tunnel handling in mice. Behavioural Brain Research, 408, 113288.
Kokash, J., Alderson, E. M., Reinhard, S. M., Crawford, C. A., Binder, D. K., Ethell, I. M., & Razak, K. A. (2019). Genetic reduction of MMP-9 in the Fmr1 KO mouse partially rescues prepulse inhibition of acoustic startle response. Brain Research, 1719, 24-29.
Kondratiuk, I., Łęski, S., Urbańska, M., Biecek, P., Devijver, H., Lechat, B., Van Leuven, F., Kaczmarek, L., & Jaworski, T. (2017). GSK-3β and MMP-9 cooperate in the control of dendritic spine morphology. Molecular Neurobiology, 54, 200-211.
Konopka, A., Grajkowska, W., Ziemiańska, K., Roszkowski, M., Daszkiewicz, P., Rysz, A., Marchel, A., Koperski, L., Wilczyński, G. M., & Dzwonek, J. (2013). Matrix metalloproteinase-9 (MMP-9) in human intractable epilepsy caused by focal cortical dysplasia. Epilepsy Research, 104, 45-58.
Korzeniewski, S. J., Allred, E. N., O'Shea, T. M., Leviton, A., Kuban, K. C. K., & ELGAN Study Investigators. (2018). Elevated protein concentrations in newborn blood and the risks of autism spectrum disorder, and of social impairment, at age 10 years among infants born before the 28th week of gestation. Translational Psychiatry, 8, 115.
Kovatsi, L., Batzios, S., Nikolaou, K., Fragou, D., Njau, S., Tsatsakis, A., Karakiulakis, G., & Papakonstantinou, E. (2013). Alterations in serum MMP and TIMP concentrations following chronic heroin abuse. Toxicology Mechanisms and Methods, 23, 377-381.
Krynicki, C. R., Dazzan, P., Pariante, C. M., Barnes, N. M., Vincent, R. C., Roberts, A., Giordano, A., Watson, A., Suckling, J., Barnes, T. R. E., Husain, N., Jones, P. B., Joyce, E., Lawrie, S. M., Lewis, S., Deakin, B., Upthegrove, R., & BeneMin Study Team. (2021). Deconstructing depression and negative symptoms of schizophrenia; differential and longitudinal immune correlates, and response to minocycline treatment. Brain, Behavior, and Immunity, 91, 498-504.
Kumarasinghe, N., Beveridge, N. J., Gardiner, E., Scott, R. J., Yasawardene, S., Perera, A., Mendis, J., Suriyakumara, K., Schall, U., & Tooney, P. A. (2013). Gene expression profiling in treatment-naive schizophrenia patients identifies abnormalities in biological pathways involving AKT1 that are corrected by antipsychotic medication. The International Journal of Neuropsychopharmacology, 16, 1483-1503.
Kyriakis, J. M. (1999). Activation of the AP-1 transcription factor by inflammatory cytokines of the TNF family. Gene Expression, 7, 217-231.
Laroui, A., Galarneau, L., Abolghasemi, A., Benachenhou, S., Plantefève, R., Bouchouirab, F. Z., Lepage, J. F., Corbin, F., & Çaku, A. (2022). Clinical significance of matrix metalloproteinase-9 in Fragile X Syndrome. Scientific Reports, 12, 15386.
Lasek, A. W., Chen, H., & Chen, W.-Y. (2018). Releasing addiction memories trapped in perineuronal nets. Trends in Genetics, 34, 197-208.
Lepeta, K., Purzycka, K. J., Pachulska-Wieczorek, K., Mitjans, M., Begemann, M., Vafadari, B., Bijata, K., Adamiak, R. W., Ehrenreich, H., Dziembowska, M., & Kaczmarek, L. (2017). A normal genetic variation modulates synaptic MMP-9 protein levels and the severity of schizophrenia symptoms. EMBO Molecular Medicine, 9, 1100-1116.
Li, H., Sheng, Z., Khan, S., Zhang, R., Liu, Y., Zhang, Y., Yong, V. W., & Xue, M. (2022). Matrix metalloproteinase-9 as an important contributor to the pathophysiology of depression. Frontiers in Neurology, 13, 861843.
Liu, T., Zhang, L., Joo, D., & Sun, S.-C. (2017). NF-κB signaling in inflammation. Signal Transduction and Targeted Therapy, 2, 17023.
López-Aranda, M. F., Chattopadhyay, I., Boxx, G. M., Fraley, E. R., Silva, T. K., Zhou, M., Phan, M., Herrera, I., Taloma, S., Mandanas, R., Bach, K., Gandal, M., Geschwind, D. H., Cheng, G., Rzhetsky, A., White, S. A., & Silva, A. J. (2021). Postnatal immune activation causes social deficits in a mouse model of tuberous sclerosis: Role of microglia and clinical implications. Science Advances, 7, eabf2073.
Lord, J. R., Mashayekhi, F., & Salehi, Z. (2022). How matrix metalloproteinase (MMP)-9 (rs3918242) polymorphism affects MMP-9 serum concentration and associates with autism spectrum disorders: A case-control study in Iranian population. Development and Psychopathology, 34, 882-888.
Lovelace, J. W., Ethell, I. M., Binder, D. K., & Razak, K. A. (2020). Minocycline treatment reverses sound evoked EEG abnormalities in a mouse model of Fragile X Syndrome. Frontiers in Neuroscience, 14, 771.
Lovelace, J. W., Rais, M., Palacios, A. R., Shuai, X. S., Bishay, S., Popa, O., Pirbhoy, P. S., Binder, D. K., Nelson, D. L., Ethell, I. M., & Razak, K. A. (2020). Deletion of Fmr1 from forebrain excitatory neurons triggers abnormal cellular, EEG, and behavioral phenotypes in the auditory cortex of a mouse model of Fragile X Syndrome. Cerebral Cortex, 30, 969-988.
Lukasiuk, K., Wilczynski, G. M., & Kaczmarek, L. (2011). Extracellular proteases in epilepsy. Epilepsy Research, 96, 191-206.
Magnowska, M., Gorkiewicz, T., Suska, A., Wawrzyniak, M., Rutkowska-Wlodarczyk, I., Kaczmarek, L., & Wlodarczyk, J. (2016). Transient ECM protease activity promotes synaptic plasticity. Scientific Reports, 6, 27757.
Martinelli, S., Anderzhanova, E. A., Bajaj, T., Wiechmann, S., Dethloff, F., Weckmann, K., Heinz, D. E., Ebert, T., Hartmann, J., Geiger, T. M., Döngi, M., Hafner, K., Pöhlmann, M. L., Jollans, L., Philipsen, A., Schmidt, S. V., Schmidt, U., Maccarrone, G., Stein, V., … Gassen, N. C. (2021). Stress-primed secretory autophagy promotes extracellular BDNF maturation by enhancing MMP9 secretion. Nature Communications, 12, 4643.
Mash, D. C., Ffrench-Mullen, J., Adi, N., Qin, Y., Buck, A., & Pablo, J. (2007). Gene expression in human hippocampus from cocaine abusers identifies genes which regulate extracellular matrix remodeling. PLoS One, 2, e1187.
Meighan, S. E., Meighan, P. C., Choudhury, P., Davis, C. J., Olson, M. L., Zornes, P. A., Wright, J. W., & Harding, J. W. (2006). Effects of extracellular matrix-degrading proteases matrix metalloproteinases 3 and 9 on spatial learning and synaptic plasticity. Journal of Neurochemistry, 96, 1227-1241.
Michaluk, P., Mikasova, L., Groc, L., Frischknecht, R., Choquet, D., & Kaczmarek, L. (2009). Matrix metalloproteinase-9 controls NMDA receptor surface diffusion through integrin beta1 signaling. The Journal of Neuroscience, 29, 6007-6012.
Miyaoka, T., Wake, R., Furuya, M., Liaury, K., Ieda, M., Kawakami, K., Tsuchie, K., Taki, M., Ishihara, K., Araki, T., & Horiguchi, J. (2012). Minocycline as adjunctive therapy for patients with unipolar psychotic depression: An open-label study. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 37, 222-226.
Mizoguchi, H., Nakade, J., Tachibana, M., Ibi, D., Someya, E., Koike, H., Kamei, H., Nabeshima, T., Itohara, S., Takuma, K., Sawada, M., Sato, J., & Yamada, K. (2011). Matrix metalloproteinase-9 contributes to kindled seizure development in pentylenetetrazole-treated mice by converting pro-BDNF to mature BDNF in the hippocampus. The Journal of Neuroscience, 31, 12963-12971.
Mizoguchi, H., Yamada, K., Mouri, A., Niwa, M., Mizuno, T., Noda, Y., Nitta, A., Itohara, S., Banno, Y., & Nabeshima, T. (2007). Role of matrix metalloproteinase and tissue inhibitor of MMP in methamphetamine-induced behavioral sensitization and reward: Implications for dopamine receptor down-regulation and dopamine release. Journal of Neurochemistry, 102, 1548-1560.
Mizoguchi, H., Yamada, K., Niwa, M., Mouri, A., Mizuno, T., Noda, Y., Nitta, A., Itohara, S., Banno, Y., & Nabeshima, T. (2007). Reduction of methamphetamine-induced sensitization and reward in matrix metalloproteinase-2 and -9-deficient mice. Journal of Neurochemistry, 100, 1579-1588.
Montagne, A., Nation, D. A., Sagare, A. P., Barisano, G., Sweeney, M. D., Chakhoyan, A., Pachicano, M., Joe, E., Nelson, A. R., D'Orazio, L. M., Buennagel, D. P., Harrington, M. G., Benzinger, T. L. S., Fagan, A. M., Ringman, J. M., Schneider, L. S., Morris, J. C., Reiman, E. M., Caselli, R. J., … Zlokovic, B. V. (2020). APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature, 581, 71-76.
Moretto, E., Murru, L., Martano, G., Sassone, J., & Passafaro, M. (2018). Glutamatergic synapses in neurodevelopmental disorders. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 84, 328-342.
Murrough, J. W., Huryk, K. M., Mao, X., Iacoviello, B., Collins, K., Nierenberg, A. A., Kang, G., Shungu, D. C., & Iosifescu, D. V. (2018). A pilot study of minocycline for the treatment of bipolar depression: Effects on cortical glutathione and oxidative stress in vivo. Journal of Affective Disorders, 230, 56-64.
Nagy, V., Bozdagi, O., Matynia, A., Balcerzyk, M., Okulski, P., Dzwonek, J., Costa, R. M., Silva, A. J., Kaczmarek, L., & Huntley, G. W. (2006). Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory. The Journal of Neuroscience, 26, 1923-1934.
Nakamoto, K., Kawasaki, S., Kobori, T., Fujita-Hamabe, W., Mizoguchi, H., Yamada, K., Nabeshima, T., & Tokuyama, S. (2012). Involvement of matrix metalloproteinase-9 in the development of morphine tolerance. European Journal of Pharmacology, 683, 86-92.
Natarajan, R., Harding, J. W., & Wright, J. W. (2013). A role for matrix metalloproteinases in nicotine-induced conditioned place preference and relapse in adolescent female rats. Journal of Experimental Neuroscience, 7, 1-14.
Nettis, M. A. (2021). Minocycline in major depressive disorder: And overview with considerations on treatment-resistance and comparisons with other psychiatric disorders. Brain, Behavior, & Immunity-Health, 17, 100335.
Okulski, P., Jay, T. M., Jaworski, J., Duniec, K., Dzwonek, J., Konopacki, F. A., Wilczynski, G. M., Sánchez-Capelo, A., Mallet, J., & Kaczmarek, L. (2007). TIMP-1 abolishes MMP-9-dependent long-lasting long-term potentiation in the prefrontal cortex. Biological Psychiatry, 62, 359-362.
Opdenakker, G., Van den Steen, P. E., & Van Damme, J. (2001). Gelatinase B: A tuner and amplifier of immune functions. Trends in Immunology, 22, 571-579.
Pijet, B., Konopka, A., Rejmak, E., Stefaniuk, M., Khomiak, D., Bulska, E., Pikul, S., & Kaczmarek, L. (2020). The matrix metalloproteinase inhibitor marimastat inhibits seizures in a model of kainic acid-induced status epilepticus. Scientific Reports, 10, 21314.
Pijet, B., Stefaniuk, M., Kostrzewska-Ksiezyk, A., Tsilibary, P.-E., Tzinia, A., & Kaczmarek, L. (2018). Elevation of MMP-9 levels promotes epileptogenesis after traumatic brain injury. Molecular Neurobiology, 55, 9294-9306.
Pirbhoy, P. S., Rais, M., Lovelace, J. W., Woodard, W., Razak, K. A., Binder, D. K., & Ethell, I. M. (2020). Acute pharmacological inhibition of matrix metalloproteinase-9 activity during development restores perineuronal net formation and normalizes auditory processing in Fmr1 KO mice. Journal of Neurochemistry, 155, 538-558.
Pitkänen, A., & Engel, J., Jr. (2014). Past and present definitions of epileptogenesis and its biomarkers. Neurotherapeutics, 11, 231-241.
Pitkänen, A., & Lukasiuk, K. (2011). Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurology, 10, 173-186.
Pitkänen, A., Ndode-Ekane, X. E., Łukasiuk, K., Wilczynski, G. M., Dityatev, A., Walker, M. C., Chabrol, E., Dedeurwaerdere, S., Vazquez, N., & Powell, E. M. (2014). Chapter 11-Neural ECM and epilepsy. In A. Dityatev, B. Wehrle-Haller, & A. Pitkänen (Eds.), Progress in brain research (pp. 229-262). Elsevier.
Protic, D., Salcedo-Arellano, M. J., Dy, J. B., Potter, L. A., & Hagerman, R. J. (2019). New targeted treatments for Fragile X Syndrome. Current Pediatric Reviews, 15, 251-258.
Puścian, A., Winiarski, M., Borowska, J., Łęski, S., Górkiewicz, T., Chaturvedi, M., Nowicka, K., Wołyniak, M., Chmielewska, J. J., Nikolaev, T., Meyza, K., Dziembowska, M., Kaczmarek, L., & Knapska, E. (2022). Targeted therapy of cognitive deficits in Fragile X Syndrome. Molecular Psychiatry, 27, 2766-2776.
Puścian, A., Winiarski, M., Łęski, S., Charzewski, Ł., Nikolaev, T., Borowska, J., Dzik, J. M., Bijata, M., Lipp, H.-P., Dziembowska, M., & Knapska, E. (2021). Chronic fluoxetine treatment impairs motivation and reward learning by affecting neuronal plasticity in the central amygdala. British Journal of Pharmacology, 178, 672-688.
Rais, M., Lovelace, J. W., Shuai, X. S., Woodard, W., Bishay, S., Estrada, L., Sharma, A. R., Nguy, A., Kulinich, A., Pirbhoy, P. S., Palacios, A. R., Nelson, D. L., Razak, K. A., & Ethell, I. M. (2022). Functional consequences of postnatal interventions in a mouse model of Fragile X Syndrome. Neurobiology of Disease, 162, 105577.
Razak, K. A., Binder, D. K., & Ethell, I. M. (2021). Neural correlates of auditory hypersensitivity in Fragile X Syndrome. Frontiers in Psychiatry, 12, 720752.
Reinhard, S. M., Razak, K., & Ethell, I. M. (2015). A delicate balance: Role of MMP-9 in brain development and pathophysiology of neurodevelopmental disorders. Frontiers in Cellular Neuroscience, 9, 280.
Reininghaus, E. Z., Lackner, N., Birner, A., Bengesser, S., Fellendorf, F. T., Platzer, M., Rieger, A., Queissner, R., Kainzbauer, N., Reininghaus, B., McIntyre, R. S., Mangge, H., Zelzer, S., Fuchs, D., Dejonge, S., & Müller, N. (2016). Extracellular matrix proteins matrix metallopeptidase 9 (MMP9) and soluble intercellular adhesion molecule 1 (sICAM-1) and correlations with clinical staging in euthymic bipolar disorder. Bipolar Disorders, 18, 155-163.
Rempe, R. G., Hartz, A. M. S., & Bauer, B. (2016). Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers. Journal of Cerebral Blood Flow and Metabolism, 36, 1481-1507.
Rivera, S., Khrestchatisky, M., Kaczmarek, L., Rosenberg, G. A., & Jaworski, D. M. (2010). Metzincin proteases and their inhibitors: Foes or friends in nervous system physiology? The Journal of Neuroscience, 30, 15337-15357.
Roeper, J. (2018). Closing gaps in brain disease-from overlapping genetic architecture to common motifs of synapse dysfunction. Current Opinion in Neurobiology, 48, 45-51.
Rosenberg, G. A. (2002). Matrix metalloproteinases in neuroinflammation. Glia, 39, 279-291.
Rybakowski, J. K., Remlinger-Molenda, A., Czech-Kucharska, A., Wojcicka, M., Michalak, M., & Losy, J. (2013). Increased serum matrix metalloproteinase-9 (MMP-9) levels in young patients during bipolar depression. Journal of Affective Disorders, 146, 286-289.
Sala, C., & Segal, M. (2014). Dendritic spines: The locus of structural and functional plasticity. Physiological Reviews, 94, 141-188.
Samochowiec, A., Grzywacz, A., Kaczmarek, L., Bienkowski, P., Samochowiec, J., Mierzejewski, P., Preuss, U. W., Grochans, E., & Ciechanowicz, A. (2010). Functional polymorphism of matrix metalloproteinase-9 (MMP-9) gene in alcohol dependence: Family and case control study. Brain Research, 1327, 103-106.
Schoretsanitis, G., de Filippis, R., Ntogka, M., Leucht, S., Correll, C. U., & Kane, J. M. (2021). Matrix metalloproteinase 9 blood alterations in patients with schizophrenia Spectrum disorders: A systematic review and meta-analysis. Schizophrenia Bulletin, 47, 986-996.
Seitz-Holland, J., Seethaler, M., Makris, N., Rushmore, J., Cho, K.-I. K., Rizzoni, E., Vangel, M., Sahin, O. S., Heller, C., Pasternak, O., Szczepankiewicz, F., Westin, C.-F., Lošák, J., Ustohal, L., Tomandl, J., Vojtíšek, L., Kudlička, P., Jáni, M., Woo, T. W., … Kubicki, M. (2022). The association of matrix metalloproteinase 9 (MMP9) with hippocampal volume in schizophrenia: A preliminary MRI study. Neuropsychopharmacology, 47, 524-530.
Shibasaki, C., Itagaki, K., Abe, H., Kajitani, N., Okada-Tsuchioka, M., & Takebayashi, M. (2018). Possible association between serum matrix metalloproteinase-9 (MMP-9) levels and relapse in depressed patients following electroconvulsive therapy (ECT). The International Journal of Neuropsychopharmacology, 21, 236-241.
Shibasaki, C., Takebayashi, M., Itagaki, K., Abe, H., Kajitani, N., Okada-Tsuchioka, M., & Yamawaki, S. (2016). Altered serum levels of matrix metalloproteinase-2, -9 in response to electroconvulsive therapy for mood disorders. The International Journal of Neuropsychopharmacology, 19, pyw019.
Shultz, R. B., & Zhong, Y. (2017). Minocycline targets multiple secondary injury mechanisms in traumatic spinal cord injury. Neural Regeneration Research, 12, 702-713.
Sidhu, H., Dansie, L. E., Hickmott, P. W., Ethell, D. W., & Ethell, I. M. (2014). Genetic removal of matrix metalloproteinase 9 rescues the symptoms of Fragile X Syndrome in a mouse model. The Journal of Neuroscience, 34, 9867-9879.
Siller, S. S., & Broadie, K. (2012). Matrix metalloproteinases and minocycline: Therapeutic avenues for Fragile X Syndrome. Neural Plasticity, 2012, 124548.
Smith, A. C. W., Kupchik, Y. M., Scofield, M. D., Gipson, C. D., Wiggins, A., Thomas, C. A., & Kalivas, P. W. (2014). Synaptic plasticity mediating cocaine relapse requires matrix metalloproteinases. Nature Neuroscience, 17, 1655-1657.
Smith, A. W., Nealey, K. A., Wright, J. W., & Walker, B. M. (2011). Plasticity associated with escalated operant ethanol self-administration during acute withdrawal in ethanol-dependent rats requires intact matrix metalloproteinase systems. Neurobiology of Learning and Memory, 96, 199-206.
Snitow, M. E., Bhansali, R. S., & Klein, P. S. (2021). Lithium and therapeutic targeting of GSK-3. Cell, 10, 255.
Sofuoglu, M., Waters, A. J., Mooney, M., & O'Malley, S. S. (2009). Minocycline reduced craving for cigarettes but did not affect smoking or intravenous nicotine responses in humans. Pharmacology, Biochemistry, and Behavior, 92, 135-140.
Stefaniuk, M., Beroun, A., Lebitko, T., Markina, O., Leski, S., Meyza, K., Grzywacz, A., Samochowiec, J., Samochowiec, A., Radwanska, K., & Kaczmarek, L. (2017). Matrix metalloproteinase-9 and synaptic plasticity in the central amygdala in control of alcohol-seeking behavior. Biological Psychiatry, 81, 907-917.
Szepesi, Z., Hosy, E., Ruszczycki, B., Bijata, M., Pyskaty, M., Bikbaev, A., Heine, M., Choquet, D., Kaczmarek, L., & Wlodarczyk, J. (2014). Synaptically released matrix metalloproteinase activity in control of structural plasticity and the cell surface distribution of GluA1-AMPA receptors. PLoS One, 9, e98274.
Szklarczyk, A., Lapinska, J., Rylski, M., McKay, R. D. G., & Kaczmarek, L. (2002). Matrix metalloproteinase-9 undergoes expression and activation during dendritic remodeling in adult hippocampus. The Journal of Neuroscience, 22, 920-930.
Thompson, S. M., Kallarackal, A. J., Kvarta, M. D., Van Dyke, A. M., LeGates, T. A., & Cai, X. (2015). An excitatory synapse hypothesis of depression. Trends in Neurosciences, 38, 279-294.
Toledo, M. A., Wen, T. H., Binder, D. K., Ethell, I. M., & Razak, K. A. (2019). Reversal of ultrasonic vocalization deficits in a mouse model of Fragile X Syndrome with minocycline treatment or genetic reduction of MMP-9. Behavioural Brain Research, 372, 112068.
Tran The, J., Magistretti, P. J., & Ansermet, F. (2022). The critical periods of cerebral plasticity: A key aspect in a dialog between psychoanalysis and neuroscience centered on the psychopathology of schizophrenia. Frontiers in Molecular Neuroscience, 15, 1057539.
Vafadari, B., Mitra, S., Stefaniuk, M., & Kaczmarek, L. (2019). Psychosocial stress induces schizophrenia-like behavior in mice with reduced MMP-9 activity. Frontiers in Behavioral Neuroscience, 13, 195.
Vafadari, B., Salamian, A., & Kaczmarek, L. (2016). MMP-9 in translation: From molecule to brain physiology, pathology, and therapy. Journal of Neurochemistry, 139(Suppl 2), 91-114.
van der Kooij, M. A., Fantin, M., Rejmak, E., Grosse, J., Zanoletti, O., Fournier, C., Ganguly, K., Kalita, K., Kaczmarek, L., & Sandi, C. (2014). Role for MMP-9 in stress-induced downregulation of nectin-3 in hippocampal CA1 and associated behavioural alterations. Nature Communications, 5, 4995.
Vandenbroucke, R. E., & Libert, C. (2014). Is there new hope for therapeutic matrix metalloproteinase inhibition? Nature Reviews. Drug Discovery, 13, 904-927.
Vandooren, J., Swinnen, W., Ugarte-Berzal, E., Boon, L., Dorst, D., Martens, E., & Opdenakker, G. (2017). Endotoxemia shifts neutrophils with TIMP-free gelatinase B/MMP-9 from bone marrow to the periphery and induces systematic upregulation of TIMP-1. Haematologica, 102, 1671-1682.
Vandooren, J., Van den Steen, P. E., & Opdenakker, G. (2013). Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade. Critical Reviews in Biochemistry and Molecular Biology, 48, 222-272.
Verslegers, M., Lemmens, K., Van Hove, I., & Moons, L. (2013). Matrix metalloproteinase-2 and -9 as promising benefactors in development, plasticity and repair of the nervous system. Progress in Neurobiology, 105, 60-78.
Vezzani, A., Friedman, A., & Dingledine, R. J. (2013). The role of inflammation in epileptogenesis. Neuropharmacology, 69, 16-24.
Wang, H.-H., Hsieh, H.-L., Wu, C.-Y., Sun, C.-C., & Yang, C.-M. (2009). Oxidized low-density lipoprotein induces matrix metalloproteinase-9 expression via a p42/p44 and JNK-dependent AP-1 pathway in brain astrocytes. Glia, 57, 24-38.
Wang, Q., Ishikawa, T., Michiue, T., Zhu, B.-L., Guan, D.-W., & Maeda, H. (2014). Molecular pathology of brain matrix metalloproteases, claudin5, and aquaporins in forensic autopsy cases with special regard to methamphetamine intoxication. International Journal of Legal Medicine, 128, 469-474.
Wang, X.-B., Bozdagi, O., Nikitczuk, J. S., Zhai, Z. W., Zhou, Q., & Huntley, G. W. (2008). Extracellular proteolysis by matrix metalloproteinase-9 drives dendritic spine enlargement and long-term potentiation coordinately. Proceedings of the National Academy of Sciences of the United States of America, 105, 19520-19525.
Wen, T. H., Afroz, S., Reinhard, S. M., Palacios, A. R., Tapia, K., Binder, D. K., Razak, K. A., & Ethell, I. M. (2017). Genetic reduction of matrix metalloproteinase-9 promotes formation of perineuronal nets around parvalbumin-expressing interneurons and normalizes auditory cortex responses in developing Fmr1 knock-out mice. Cerebral Cortex, 28, 3951-3964.
Wiera, G., Wozniak, G., Bajor, M., Kaczmarek, L., & Mozrzymas, J. W. (2013). Maintenance of long-term potentiation in hippocampal mossy fiber-CA3 pathway requires fine-tuned MMP-9 proteolytic activity. Hippocampus, 23, 529-543.
Wilczynski, G. M., Konopacki, F. A., Wilczek, E., Lasiecka, Z., Gorlewicz, A., Michaluk, P., Wawrzyniak, M., Malinowska, M., Okulski, P., Kolodziej, L. R., Konopka, W., Duniec, K., Mioduszewska, B., Nikolaev, E., Walczak, A., Owczarek, D., Gorecki, D. C., Zuschratter, W., Ottersen, O. P., & Kaczmarek, L. (2008). Important role of matrix metalloproteinase 9 in epileptogenesis. The Journal of Cell Biology, 180, 1021-1035.
Yan, P., Hu, X., Song, H., Yin, K., Bateman, R. J., Cirrito, J. R., Xiao, Q., Hsu, F. F., Turk, J. W., Xu, J., Hsu, C. Y., Holtzman, D. M., & Lee, J.-M. (2006). Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. The Journal of Biological Chemistry, 281, 24566-24574.
Yeghiazaryan, M., Rutkowska-Wlodarczyk, I., Konopka, A., Wilczyński, G. M., Melikyan, A., Korkotian, E., Kaczmarek, L., & Figiel, I. (2014). DP-b99 modulates matrix metalloproteinase activity and neuronal plasticity. PLoS One, 9, e99789.
Yin, K.-J., Cirrito, J. R., Yan, P., Hu, X., Xiao, Q., Pan, X., Bateman, R., Song, H., Hsu, F.-F., Turk, J., Xu, J., Hsu, C. Y., Mills, J. C., Holtzman, D. M., & Lee, J.-M. (2006). Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism. The Journal of Neuroscience, 26, 10939-10948.
Yin, L.-T., Xie, X.-Y., Xue, L.-Y., Yang, X.-R., Jia, J., Zhang, Y., & Zhang, C. (2020). Matrix metalloproteinase-9 overexpression regulates hippocampal synaptic plasticity and decreases alcohol consumption and preference in mice. Neurochemical Research, 45, 1902-1912.
Yu, Z., Fang, X., Liu, W., Sun, R., Zhou, J., Pu, Y., Zhao, M., Sun, D., Xiang, Z., Liu, P., Ding, Y., Cao, L., & He, C. (2022). Microglia regulate blood-brain barrier integrity via MiR-126a-5p/MMP9 axis during inflammatory demyelination. Advancement of Science, 9, e2105442.
Zhang, J. W., Deb, S., & Gottschall, P. E. (1998). Regional and differential expression of gelatinases in rat brain after systemic kainic acid or bicuculline administration. The European Journal of Neuroscience, 10, 3358-3368.